Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade

Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade

Tumor associated neutrophils have been correlated with poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). Here the authors show that the tyrosine kinase inhibitor lorlatinib modulates neutrophil development and recruitment in the tumor microenvironment, attenuating PDAC progres...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sebastian R. Nielsen, Jan E. Strøbech, Edward R. Horton, Rene Jackstadt, Anu Laitala, Marina C. Bravo, Giorgia Maltese, Adina R. D. Jensen, Raphael Reuten, Maria Rafaeva, Saadia A. Karim, Chang-Il Hwang, Luis Arnes, David A. Tuveson, Owen J. Sansom, Jennifer P. Morton, Janine T. Erler
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/80c3347050694832b4503df3a10d5b8d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/80c3347050694832b4503df3a10d5b8d

Ejemplares similares